Header Background.jpg

PUBLICATIONS

Faknostics Logo.png
OUR PUBLISHED EXPERTISE ON THE APPLICABILITY OF FAK-TARGETED THERAPEUTICS IN MULTIPLE TYPES OF CANCER

BREAST CANCER

Golubovskaya V, Beviglia L, Xu L-H, Earp HS, Craven R, Cance WG.  Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells.  J Biol Chem 2002; 277(41):38978-38987. PMID: 12167618

Lark AL, Livasy CA, Dressler L, Moore DT, Millikan RC, Geradts J, Iacocca M, Cowan D, Little D, Craven RJ, Cance WG.  High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype.  Mod Pathol 2005; 18:1289-1294. PMID: 15861214

Golubovskaya VM, Zheng M, Zhang L, Li J-L, Cance WG.  The direct effect of  focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis.  BMC Cancer 2009; 12(9):280.  PMID: 19671193

Golubovskaya VM, Ylagan L, Miller A, Hughes M, Wilson J, Wang D, Brese E, Bshara W, Edge S, Morrison C, Cance, WG.  High focal adhesion kinase expression in breast carcinoma is associated with lymphovascular invasion and triple-negative phenotype.  BMC Cancer October 2014; 14(1): 769.  PMID:  25326692

COLORECTAL CANCER

Lik Hang Lee, Lindy Davis, Lourdes Ylagan, Angela R Omilian, Kristopher Attwood,

Canan Firat, Jinru Shia, Philip B Paty, William G Cance. Identification of a Subset of Stage Journal of the National Cancer Institute 

https://doi.org/10.1093/jnci/djac023

Lark AL, Livasy C, Calvo B, Caskey L, Moore DT, Yang X-H, Cance WG. Overexpression of focal adhesion kinase (FAK) in primary colorectal carcinomas and colorectal liver metastases: Immunohistochemistry and real-time PCR analyses.  Clin Cancer Res 2003; 9(1):215-222. PMID: 12538472

Heffler M, Golubovskaya VM, Bullard Dunn K, Cance W.  Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.  Cancer Biol Ther  2013; 14(8): 761- 772.  PMID: 23792569

 

LUNG CANCER

Dy G, Golubovskaya V, Ylagan L, Pokharel S, Bshara W, Brese E, Morrison C, Cance WG, Miller A.  The  prognostic significance of focal adhesion kinase (FAK) expression in stage I non-small cell lung cancer.  J Thorac Oncol 2014:9:1278-1284.  PMID:  25122425

Zhang H, Shao H, Golubovskaya V, Chen H, Cance WG, Adjei A, Dy G. Efficacy of focal adhesion kinase (FAK) inhibition in non-small cell lung cancer with oncogenically-activated MAPK pathways. Br J Cancer. 2016; 115(2): 203-11. PMID: 2733608.

MELANOMA

Smith CS, Golubovskaya VM, Peck E, Xu L-H, Monia BP, Yang, X, Cance WG.  Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines.  Melanoma Res 2005; 15(5):357-362.  PMID: 16179862

Ucar DA, Kurenova E, Garrett TJ, Cance WG, Nyberg C, Cox A, Massoli N, Ostrov DA, Lawrence N, Sebti SM, Zajac-Kaye M, Hochwald SN.  Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth.  Cell Cycle 2012; 11(17): 3250-3259.  PMID:  22894899

Kurenova E, Ucar D, Liao J, Yemma M, Gogate P, Bshara W, Sunar U, Seshadri M, Hochwald S, Cance WG.  A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.  Cell Cycle 2014; 13 (16): 2542-2553.  PMID:  25486195

GLIOBLASTOMA

Golubovskaya V, Huang G, Baotran H, Yemma M, Morrison C, Lee J, Eliceiri B, Cance WG.  Pharmacological blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.  Mol Cancer Ther 2013; 12(2): 162 - 172.  PMID:  23243059

SARCOMA

Owens LV, Weiner, T Xu L, Cance WG.  Antisense to the focal adhesion kinase gene disrupts human sarcoma growth and adhesion.  Surg Forum 1994; 45:501-503.

THYROID CANCER

Owens LV, Xu L-H, Dent GA, Yang X-H, Sturge GC, Craven RJ, Cance WG.  Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer.  Ann Surg Oncol 1996; 3(1):100-105. PMID: 8770310

O’Brien S, Golubovskaya VM, Conroy J, Liu S, Wang D, Liu B, Cance, WG.  FAK inhibition with small molecule inhibitor Y15 decreased viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics. Oncotarget 2014; 5(17): 7945-7959.  PMID:  25277205.

OVARIAN CANCER

Judson PL, He X, Cance WG, Van Le L.  Over-expression of focal adhesion kinase a protein tyrosine kinase in ovarian carcinoma.  Cancer 1999; 86(8):1551-1556. PMID: 10526262

NEUROBLASTOMA

Beierle EA, Trujillo A, Nagaram A, Golubovskaya VM, Cance WG, Kurenova EV. TAE226 inhibits human neuroblastoma cell survival. Cancer Invest 2008; 26(2):145-151.  PMID: 18259944

Beierle EA, Massoll NA, Hartwich J, Kurenova EV, Golubovskaya VM, Cance WG, McGrady P, London WB.: Focal adhesion kinase expression in human neuroblastoma: Immunohistochemical and real-time PCR analyses. Clin Cancer Res 2008; 14(11):3299-3305. PMID: 18519756

Beierle EA, Trujillo A, Kurenova EV, Cance WG, Golubovskaya VM.  Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines.  Mol Carcinog 2010; 49(3):224-234. PMID: 19885861

Beierle EA, Ma X, Stewart J, Nyberg C, Trujillo A, Cance WG, Golubovskaya VM. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle 2010; 9(5)1005-1015. PMID: 20160475

Stewart JE, Ma X, Megison M, Nabers H, Cance WG, Kurenova EV, Beirele EA.  Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma.  Mol Carcinog. 2013 July 19. [Epub ahead of print].  PMID:  23868727

PANCREATIC CANCER

Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, Hochwald SN. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 2008; 29(6)1096-1107.PMID: 18263593

Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, Massoll NA, Magis A, Ostrov D, Cance WG, Golubovskaya V.  A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.  Cell Cycle 2009; 8(15):2435-2443. PMID: 19571674

Zheng D, Golubovskaya V, Kurenova E, Wood C, Massoll NA, Ostrov D, Cance WG, Hochwald SN. A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts. Mol Carcinog 2010; 49(2):200-209.  PMID: 19885860

Kurenova E, Liao J, He DH, Hunt D, Yemma M, Bshara W, Seshadri M, Cance WG.  The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.  Oncotarget 2013; 4 (10):  1632-1646.  PMID:  24142503

Gogate P, Kurenova E, Ethirajan M, Liao J, Yemma M, Sen A, Pandey R, Cance WG.  Targeting the C-terminal focal adhesion kinase scaffold in pancreatic cancer.  Cancer Lett Jul 2014.  [E-pub ahead of print].  PMID:  25067788